Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cyclacel Pharmaceuticals (CYCC)
:CYCC
Holding CYCC?
Track your performance easily
CYCC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.31 - $4.00
Previous CloseN/A
Volume644.75K
Average Volume (3M)4.39M
Market Cap
$3.97M
Enterprise Value-$851.32K
Total Cash (Recent Filing)$16.52M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Apr 01, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.21
Shares Outstanding11,256,133
10 Day Avg. Volume12,330,679
30 Day Avg. Volume4,392,413
Standard Deviation0.26
R-Squared0.00519
Alpha-0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)29.94
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.21
Enterprise Value/Revenue-11.50
Enterprise Value/Gross Profit-2.03
Enterprise Value/Ebitda0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Cyclacel Pharmaceuticals News
PremiumCompany Announcements
Cyclacel Pharmaceuticals Restructures Leadership and Financial Strategy
PremiumCompany Announcements
Cyclacel Pharmaceuticals Reports Q3 2024 Financial Results
Ownership Overview
1.02% Insiders
0.12% Mutual Funds
1.29% Other Institutional Investors
97.51% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CYCC FAQ
What was Cyclacel Pharmaceuticals’s price range in the past 12 months?
Cyclacel Pharmaceuticals lowest stock price was $0.31 and its highest was $4.00 in the past 12 months.
What is Cyclacel Pharmaceuticals’s market cap?
Cyclacel Pharmaceuticals’s market cap is $3.97M.
When is Cyclacel Pharmaceuticals’s upcoming earnings report date?
Cyclacel Pharmaceuticals’s upcoming earnings report date is Apr 01, 2025 which is in 70 days.
How were Cyclacel Pharmaceuticals’s earnings last quarter?
Cyclacel Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.54 by $0.36.
Is Cyclacel Pharmaceuticals overvalued?
According to Wall Street analysts Cyclacel Pharmaceuticals’s price is currently Overvalued.
Does Cyclacel Pharmaceuticals pay dividends?
Cyclacel Pharmaceuticals does not currently pay dividends.
What is Cyclacel Pharmaceuticals’s EPS estimate?
Cyclacel Pharmaceuticals’s EPS estimate is -0.29.
How many shares outstanding does Cyclacel Pharmaceuticals have?
Cyclacel Pharmaceuticals has 11,256,133 shares outstanding.
What happened to Cyclacel Pharmaceuticals’s price movement after its last earnings report?
Cyclacel Pharmaceuticals reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.54. Following the earnings report the stock price went up 9.756%.
Which hedge fund is a major shareholder of Cyclacel Pharmaceuticals?
Currently, no hedge funds are holding shares in CYCC
---
Company Description
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.
---
CYCC Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with significant progress in the clinical development of fadra and a strong financial position, despite some challenges in R&D tax credits and increased expenses for topogezotitib.Read More>---
Technical Analysis
Advaxis
―
SELLAS Life Sciences Group
―
Palvella Therapeutics
―
Fennec Pharmaceuticals
―
---